XENE Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024

VANCOUVER, British Columbia, March 05, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced that the company will present at Leerink Partners Global Biopharma Conference 2024 to be held in Miami, FL on March 11-13, 2024.

Company Fireside Chat Presentation Details:

Date:Monday, March 11, 2024
  
Time:11:20 AM Eastern Time
  
Webcast:
  
Presenters:Ian Mortimer, President and Chief Executive Officer
 Sherry Aulin, Chief Financial Officer
  

A live webcast of the company presentation will be available on the “” section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (Nasdaq:XENE) is a neuroscience-focused biopharmaceutical company committed to discovering, developing, and commercializing innovative therapeutics to improve the lives of people living with neurological and psychiatric disorders. We are advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. For more information, please visit .

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Contacts:

For Investors:

Chad Fugere

Vice President, Investor Relations

(857) 675-7275

For Media:

Jodi Regts

Xenon Corporate Affairs

(604) 484-3353





EN
05/03/2024

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Xenon Pharmaceuticals Inc

 PRESS RELEASE

Xenon Reports Second Quarter 2025 Financial Results & Business Update

Xenon Reports Second Quarter 2025 Financial Results & Business Update – Phase 3 azetukalner X-TOLE2 FOS study patient recruitment complete, with topline data anticipated in early 2026– Phase 3 azetukalner neuropsychiatric studies underway with X-NOVA3 in MDD and X-CEED in BPD recently initiated– Phase 1 healthy volunteer study initiated for lead Nav1.7 development candidate for pain– Darren Cline appointed as Chief Commercial Officer to lead commercial build and anticipated azetukalner launch– Conference call at 4:30 pm ET today VANCOUVER, British Columbia and BOSTON, Aug. 11, 2025 (GLOB...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch